|[April 14, 2014]
Research and Markets: Japan Schizophrenia Drug Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/v77gdj/pharmapoint)
has announced the addition of the "PharmaPoint:
Schizophrenia - Japan Drug Forecast and Market Analysis to 2022"
report to their offering.
The youth of Japan's schizophrenia drug market will drive a significant
period of growth over the forecast period. Disease management in Japan
uses LAIs less often than the countries in the EU, and the US as well.
However, their growing role in schizophrenia treatment is driving a
growing popularity in Japan, and the uptake of new LAI therapies should
Overview of Schizophrenia including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
Detailed information on the key drugs in Japan including product
description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Japan from 2012-2022.
Analysis of the impact of key events as well the drivers and
restraints affecting the Japan Schizophrenia market.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
3.1 Etiology and Pathophysiology
4 Disease Management
4.2 Treatment Overview
Treatment of Acute Agitation Associated with Schizophrenia
Maintenance Treatment of Schizophrenia
5 Competitive Assessment
5.2 Strategic Competitor Assessment
5.3 Product Profiles by Generation
6 Opportunity and Unmet Need
6.1 Unmet Needs Overview
Early Diagnosis and Treatment
Long-Acting and Advanced Drug Delivery Systems
Effective Management of Negative and Cognitive Symptom Domains
6.2 Gap Analysis
Long-Acting Drug Delivery
Treatment of Negative and Cognitive Symptoms
7 Pipeline Assessment
7.2 Early-Stage Pipeline Assessment
7.3 Novel Therapeutic Approaches
7.4 Long-Acting Drug Delivery
7.5 Technology Trends Analysis
7.6 Key Drugs in Clinical Development
8 Market Outlook
Drivers and Barriers
[ Back To Technology News's Homepage ]